Syndax Pharmaceuticals, Inc. Non Peo Neo Avg Total Comp Amt
Syndax Pharmaceuticals, Inc. (SNDX) reported Non Peo Neo Avg Total Comp Amt of $2.45 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-30.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-30
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.45M DEF 14A · filed 2026-04-30 |
| 2024-12-31 | $2.62M DEF 14A · filed 2026-04-30 |
| 2023-12-31 | $3.03M DEF 14A · filed 2026-04-30 |
| 2022-12-31 | $2.36M DEF 14A · filed 2026-04-30 |
| 2021-12-31 | $2.56M DEF 14A · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |